Svar Life Science

September 26, 2023

Presenting the Ultimate iLite® Complement-Dependent Cytotoxicity (CDC) Bioassay Solution with Extended Adaptation Capabilities

Are you seeking a robust, specific, and fast characterization of Complement-dependent cytotoxicity (CDC) response for your therapeutic antibodies? Look no further!

Introducing our assay-ready solution, designed to accurately detect cell lysis triggered by CDC. We are excited to offer the iLite® CDC bioassay, which provides unmatched adaptability for assessing Ab-induced CDC response and CDC inhibition by complement-targeted therapeutics.

The assay presents great customization possibilities to generate a cell line with your surface antigens of interest, allowing you to pinpoint the Mechamis of Action (MoA).

Our CDC bioassay is a game-changing solution to streamline your antibody characterization or complement target therapeutic.

September 26, 2023

Presenting the Ultimate iLite® Complement-Dependent Cytotoxicity (CDC) Bioassay Solution with Extended Adaptation Capabilities

Are you seeking a robust, specific, and fast characterization of Complement-dependent cytotoxicity (CDC) response for your therapeutic antibodies? Look no further!

Introducing our assay-ready solution, designed to accurately detect cell lysis triggered by CDC. We are excited to offer the iLite® CDC bioassay, which provides unmatched adaptability for assessing Ab-induced CDC response and CDC inhibition by complement-targeted therapeutics.

The assay presents great customization possibilities to generate a cell line with your surface antigens of interest, allowing you to pinpoint the Mechamis of Action (MoA).

Our CDC bioassay is a game-changing solution to streamline your antibody characterization or complement target therapeutic.


The CDC (complement-dependent cytotoxicity) mechanism plays a vital role in the immune response by engaging both innate and adaptive immunity. Gaining a deep understanding of CDC is essential for advancing antibody development, especially for engineered antibodies that induce CDC, such as those used in oncology or other therapeutic areas where CDC response is an undesirable side effect.

Additionally, CDC is a critical factor in complement-targeted therapeutic development, as it represents the final step in the classical activation pathway.
 


These key aspects of the new iLite® CDC bioassays can enhance your CDC testing for therapeutic antibody development:

 

A true measure of CDC-induced cell lysis 

It offers a biological significance assay by incorporating Svar LUC, a clever nuclear luciferase construct that remains trapped in the nucleus until cell lysis occurs.  This innovative approach enables the detection of even subtle changes in the CDC response.

Extended Customization Possibilities 

It presents unparalleled adaptability since it allows for customization by expressing surface antigens of interest to evaluate the cytotoxic effects of a wide variety of antibodies. 

Measuring wanted and unwanted Ab-mediated effects in one cell line

It is versatile since it allows you to detect (wanted and unwanted) Ab-mediated cytotoxic effects of therapeutic antibodies with agonistic, antagonistic, or neutralizing functions in functional assays using only one target cell line.

Suitable for assessing complement targeting therapeutics

It is well-suited to assess complement targeting therapeutics. By measuring cell lysis induced by complement activation, the assay provides valuable information about the efficacy and potency of complement-targeting therapeutics. 

 

The new CDC bioassay represents a significant leap forward in your therapeutic antibody testing. Its unique reporter gene system offers unparalleled adaptability, simplicity, and sensitivity. With the CDC bioassay, you can confidently measure cell lysis induced by CDC, optimize therapeutic antibody candidates, and drive advancements in your drug development.

 

Enhance your antibody characterization with iLite's power of three

Transform your therapeutic development with our Antibody Characterization Assays, including ADCC, ADCP, and the newly introduced CDC, which offer optimal bioassays for assessing the full range of Fc-induced antibody-dependent cytotoxic effects.

 

Read more about our new iLite CDC bioassay!